

---

# PRESS RELEASE

## GeneCards® Version 3.0 Released

**Hanover, MA, USA, March 2, 2010:** Xennex Inc. (Xennex) announced today the release of GeneCards®, Version 3.0, available at [www.genecards.org](http://www.genecards.org).

GeneCards Version 3.0 was introduced as a trial release in May 2009 and is now the default version at [www.genecards.org](http://www.genecards.org). V3 features significantly upgraded infrastructure, including a comprehensive relational biological database, and a novel, sophisticated and speedier search engine. It provides capabilities for highly effective and well targeted queries, a user friendly display and clear data navigation. Also released is the enhanced GeneDecks Version 3, which makes use of the new GeneCards relational database for complex analyses on sets of genes. With GeneCards Version 3.0, Xennex's customers will be able to integrate GeneCards data into their internal systems, and perform comprehensive data mining.

Dr. David Warshawsky, Chairman of Xennex, stated: "We are delighted to see the deployment of GeneCards Version 3.0. It will enable users around the world to better perform cutting edge research in various fields of biology and medicine, and in the discovery and development of diagnostics and therapeutics."

### About GeneCards®

GeneCards® ([www.genecards.org](http://www.genecards.org)) is a searchable, integrated, database of human genes that provides concise genomic, transcriptomic, genetic, proteomic, functional

and disease related information on all known and predicted human genes. Information is featured in 18 GeneCards sections and includes orthologies, disease relationships, mutations and SNPs, gene expression, gene function, pathways, protein-protein interactions, related drugs & compounds and direct links to valuable research reagents and tools such as antibodies, recombinant proteins, clones, expression assays and RNAi reagents. GeneCards was developed over the last 13 years by a world-leading bioinformatics team at the Weizmann Institute of Science in Israel, directed by Marilyn Safran and by Professor Doron Lancet of the Department of Molecular Genetics, Head of the Crown Human Genome Center, and the incumbent of the Ralph & Lois Silver Professorial Chair of Human Genomics at the Weizmann Institute of Science.

#### About Xennex, Inc.

Founded in 2003, Xennex, Inc. ([www.xennexinc.com](http://www.xennexinc.com)) is a dynamic privately held company that is dedicated to providing Biotechnology, Pharmaceutical and other life sciences companies, as well as organizations dealing with biotechnology intellectual property, the highest level of services and tools to enhance their gene-based research. Xennex' products help such organizations to optimize their efforts to develop innovative medical products and services.

Xennex' customers include many of the world's leading biotech and pharmaceutical companies and organizations dealing with intellectual property, located in North America, Europe and Japan. Xennex' products are used in hundreds of commercial and academic organizations by tens of thousands of users around the globe

#### For further information please contact:

Kenneth Elsner

General Counsel and CFO

Xennex Inc.

Tel: +1 781 826 7719

kelsner@xennexinc.com